A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

NCT07347249

Status	RECRUITING
Phase	Phase 2
Sponsor	Hemab ApS
Enrollment	18 participants

Key Eligibility Criteria

Inclusion (4)

- Age 18 to 60 years, inclusive, at the time of signing informed consent.
- Diagnosis of FVIID defined by Factor VII:C activity \< 10% documented on e 2 different laboratory measurements by local laboratory assessment.
- Severe bleeding history characterized by history of a major bleeding event and/or receipt of recombinant activated FVII or fresh frozen plasma as treatment for bleeding or a severe clinical bleeding history as defined by the Investigator.
- Has the ability to provide informed consent to participate in the trial.

Exclusion (7)

- Presence of known inhibitors to FVII or FVIIa
- History of clinically significant hypersensitivity associated with monoclonal antibody therapies.
- History of venous or arterial thrombosis or thromboembolic disease, with the exception of catheter-associated superficial vein thrombosis.
- Known thrombophilia risk by the following criteria: Homozygous Factor V Leiden (FVL), compound heterozygous FVL/Prothrombin gene mutation, antithrombin \<50%, congenital protein C, and protein S deficiency with levels \<50%.
- Clinically significant comorbidity that may interfere with study participation.

... and 2 more (see full listing online)

Locations (1 total)

Royal London Hospital, London, United Kingdom

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.